OncoMatch/Clinical Trials/NCT06840119
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Is NCT06840119 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for cancer.
Treatment: IMC-R117C · Chemotherapy drug · Chemotherapy drug · Kinase inhibitor · Antiangiogenic Agent · Monoclonal antibody — This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: applicable standard treatments
Previously received applicable standard treatments
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify